RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO – Get Free Report) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 1,444 shares, a growth of 618.4% from the July 15th total of 201 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 3,592 shares, the days-to-cover ratio is presently 0.4 days.
RCN Pareto Strategic Allocation ETF Price Performance
Shares of RCN Pareto Strategic Allocation ETF stock remained flat at $28.18 during trading on Wednesday. 8 shares of the stock were exchanged. RCN Pareto Strategic Allocation ETF has a 12 month low of $24.68 and a 12 month high of $28.18. The stock has a market cap of $625.00 million, a PE ratio of -29.35 and a beta of 0.60.
One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.
Recommended Stories
- Five stocks we like better than RCN Pareto Strategic Allocation ETF
- CoreWeave’s $129 Billion AI Backlog Changes the Bull Case
- Tesla’s Robotaxi Reality Check: Time to Deliver
- Hims & Hers’ Revenue Beat Came With a Profitability Problem
- A Westinghouse IPO Could Reset the Nuclear Stock Conversation
Receive News & Ratings for RCN Pareto Strategic Allocation ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RCN Pareto Strategic Allocation ETF and related companies with MarketBeat.com's FREE daily email newsletter.
